Ruxolitinib (trade name: Jakavi) has been approved since March 2015 for the treatment of adults with polycythaemia vera, a rare disease of the bone marrow. It can be used when the drug hydroxyurea is ineffective or not tolerated. ...
Aug 7, 2015
0
6
(HealthDay)—Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow.
Dec 4, 2014
0
0
Joseph Pidala, M.D., M.S., assistant member of the Blood and Bone Marrow Transplant and Immunology programs at Moffitt Cancer Center, and colleagues from the Chronic Graft-Versus-Host Disease Consortium have determined that ...
Jun 17, 2013
0
0
Fanconi anemia (FA) is a rare genetic disorder which affects one person in 350,000. People affected by this disease have defects in DNA repair, and are hypersensitive to oxidative damage, resulting in bone marrow failure ...
May 15, 2012
0
0
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius ...
Jun 14, 2011
0
0
